[1]

Kudira R, Yang ZF, Osuji I, Damen MSMA, Yang vom Hofe A, et al. 2025. Bile acids engage the SIPR-STAT3 signaling axis to modulate regulatory T cell responses in fibrosing cholangiopathies. Journal of Hepatology 83:1128−1141

doi: 10.1016/j.jhep.2025.05.032
[2]

Yang C, Guo G, Li B, Zheng L, Sun R, et al. 2023. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatology International 17:237−248

doi: 10.1007/s12072-022-10431-7
[3]

Corson TW, Crews CM. 2007. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130:769−774

doi: 10.1016/j.cell.2007.08.021
[4]

Xu S, Feng Y, He W, Xu W, Xu W, et al. 2021. Celastrol in metabolic diseases: progress and application prospects. Pharmacological Research 167:105572

doi: 10.1016/j.phrs.2021.105572
[5]

Guo J, Wang Y, Wang N, Bai Y, Shi D. 2019. Celastrol attenuates intrahepatic cholestasis of pregnancy by inhibiting matrix metalloproteinases-2 and 9. Annals of Hepatology 18:40−47

doi: 10.5604/01.3001.0012.7860
[6]

Zhao Q, Liu F, Cheng Y, Xiao XR, Hu DD, et al. 2019. Celastrol protects from cholestatic liver injury through modulation of SIRT1-FXR signaling. Molecular & Cellular Proteomics 18:520−533

doi: 10.1074/mcp.RA118.000817
[7]

Wang Z, Zhang T, Wang B, Li S. 2025. TCM network pharmacology: new perspective integrating network target with artificial intelligence and multi-modal multi-omics technologies. Chinese Journal of Natural Medicines 23:1425−1434

doi: 10.1016/s1875-5364(25)60986-1
[8]

Wang J, Xu Y, Chen Z, Liang J, Lin Z, et al. 2020. Liver immune profiling reveals pathogenesis and therapeutics for biliary atresia. Cell 183:1867−1883.e26

doi: 10.1016/j.cell.2020.10.048
[9]

Ye C, Zhu J, Wang J, Chen D, Meng L, et al. 2022. Single-cell and spatial transcriptomics reveal the fibrosis-related immune landscape of biliary atresia. Clinical and Translational Medicine 12:e1070

doi: 10.1002/ctm2.1070
[10]

Paiva RA, Salou M. 2025. MAIT and iNKT cells in tissue homeostasis and repair. Immunobiology 230:152917

doi: 10.1016/j.imbio.2025.152917
[11]

Hebbandi Nanjundappa R, Shao K, Krishnamurthy P, Gershwin ME, Leung PSC, et al. 2024. Invariant natural killer T cells in autoimmune cholangiopathies: mechanistic insights and therapeutic implications. Autoimmunity Reviews 23:103485

doi: 10.1016/j.autrev.2023.103485
[12]

Ruiz-Blázquez P, Pistorio V, Fernández-Fernández M, Moles A. 2021. The multifaceted role of cathepsins in liver disease. Journal of Hepatology 75:1192−1202

doi: 10.1016/j.jhep.2021.06.031
[13]

Meng J, Wang Q, Wang H, Shen X, Qin T, et al. 2025. Natural products targeting NLRP3 inflammasome for metabolic dysfunction-associated fatty liver disease: the known unknowns. Chinese Journal of Natural Medicines 23:1036−1046

doi: 10.1016/s1875-5364(25)60970-8
[14]

Brown R, Nath S, Lora A, Samaha G, Elgamal Z, et al. 2020. Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics. Respiratory Research 21:111

doi: 10.1186/s12931-020-01381-5
[15]

de Mingo Pulido Á, de Gregorio E, Chandra S, Colell A, Morales A, et al. 2018. Differential role of cathepsins S and B in hepatic APC-mediated NKT cell activation and cytokine secretion. Frontiers in Immunology 9:391

doi: 10.3389/fimmu.2018.00391
[16]

Kong W, Li X, Zou M, Zhang Y, Cai H, et al. 2023. iNKT17 cells play a pathogenic role in ethinylestradiol-induced cholestatic hepatotoxicity. Archives of Toxicology 97:561−580

doi: 10.1007/s00204-022-03403-1
[17]

Nong C, Zou M, Xue R, Bai L, Liu L, et al. 2020. The role of invariant natural killer T cells in experimental xenobiotic-induced cholestatic hepatotoxicity. Biomedicine & Pharmacotherapy 122:109579

doi: 10.1016/j.biopha.2019.109579
[18]

Zhang J, Yan J, Dong H, Zhang R, Chang J, et al. 2025. Dimeric sesquiterpenoids with anti-inflammatory activities from Inula britannica. Chinese Journal of Natural Medicines 23:961−971

doi: 10.1016/s1875-5364(25)60931-9
[19]

Sun CP, Zhou JJ, Yu ZL, Huo XK, Zhang J, et al. 2022. Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model. Proceedings of the National Academy of Sciences of the United States of America 119:e2118818119

doi: 10.1073/pnas.2118818119
[20]

Wang H, Feng D, Park O, Yin S, Gao B. 2013. Invariant NKT cell activation induces neutrophil accumulation and hepatitis: opposite regulation by IL-4 and IFN-γ. Hepatology 58:1474−1485

doi: 10.1002/hep.26471
[21]

Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, et al. 2000. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. The Journal of Experimental Medicine 191:105−114

doi: 10.1084/jem.191.1.105
[22]

Zhou Y, Huang X, Yu H, Shi H, Chen M, et al. 2023. TMT-based quantitative proteomics revealed protective efficacy of Icariside II against airway inflammation and remodeling via inhibiting LAMP2, CTSD and CTSS expression in OVA-induced chronic asthma mice. Phytomedicine 118:154941

doi: 10.1016/j.phymed.2023.154941
[23]

Park O, Jeong WI, Wang L, Wang H, Lian ZX, et al. 2009. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49:1683−1694

doi: 10.1002/hep.22813
[24]

Jeong WI, Park O, Radaeva S, Gao B. 2006. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44:1441−1451

doi: 10.1002/hep.21419
[25]

Luo P, Liu D, Zhang Q, Yang F, Wong YK, et al. 2022. Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1. Acta Pharmaceutica Sinica B 12:2300−2314

doi: 10.1016/j.apsb.2021.12.007
[26]

Fan N, Zhang X, Zhao W, Zhao J, Luo D, et al. 2022. Covalent inhibition of pyruvate kinase M2 reprograms metabolic and inflammatory pathways in hepatic macrophages against non-alcoholic fatty liver disease. International Journal of Biological Sciences 18:5260−5275

doi: 10.7150/ijbs.73890
[27]

Zeissig S, Peuker K, Iyer S, Gensollen T, Dougan SK, et al. 2017. CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation. Proceedings of the National Academy of Sciences of the United States of America 114:10449−10454

doi: 10.1073/pnas.1701428114
[28]

Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, et al. 2014. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26:549−564

doi: 10.1016/j.ccell.2014.09.003
[29]

Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, et al. 2002. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123:1031−1043

doi: 10.1053/gast.2002.36020
[30]

Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, et al. 2010. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51:1998−2007

doi: 10.1002/hep.23599
[31]

Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, et al. 2012. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 61:1323−1329

doi: 10.1136/gutjnl-2011-301857
[32]

Ishikawa S, Ikejima K, Yamagata H, Aoyama T, Kon K, et al. 2011. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. Journal of Hepatology 54:1195−1204

doi: 10.1016/j.jhep.2010.08.022
[33]

Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, et al. 2007. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 26:117−129

doi: 10.1016/j.immuni.2006.11.011
[34]

de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, et al. 2004. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. The Journal of Immunology 173:1417−1425

doi: 10.4049/jimmunol.173.2.1417
[35]

Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, et al. 2006. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130:435−452

doi: 10.1053/j.gastro.2005.10.055
[36]

de Mingo Á, de Gregorio E, Moles A, Tarrats N, Tutusaus A, et al. 2016. Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation. Cell Death & Disease 7:e2464

doi: 10.1038/cddis.2016.368
[37]

Werneburg N, Guicciardi ME, Yin XM, Gores GJ. 2004. TNF-α-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. American Journal of Physiology-Gastrointestinal and Liver Physiology 287:G436−G443

doi: 10.1152/ajpgi.00019.2004
[38]

Zhang J, Zhang M, Huo XK, Ning J, Yu ZL, et al. 2023. Macrophage inactivation by small molecule wedelolactone via targeting sEH for the treatment of LPS-induced acute lung injury. ACS Central Science 9:440−456

doi: 10.1021/acscentsci.2c01424
[39]

Zhang J, Zhang HL, Xu XR, Feng YL, Zhu QM, et al. 2025. Targeting PBK with small-molecule 1-O-acetyl-4R, 6S-britannilactone for the treatment of neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America 122:e2502593122

doi: 10.1073/pnas.2502593122
[40]

Zhang J, Luan ZL, Huo XK, Zhang M, Morisseau C, et al. 2023. Direct targeting of sEH with alisol B alleviated the apoptosis, inflammation, and oxidative stress in cisplatin-induced acute kidney injury. International Journal of Biological Sciences 19:294−310

doi: 10.7150/ijbs.78097
[41]

Yang M, Liu J, Shao J, Qin Y, Ji Q, et al. 2014. Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Molecular Cancer 13:43

doi: 10.1186/1476-4598-13-43
[42]

Huang CC, Chen KL, Cheung CHA, Chang JY. 2013. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radical Biology and Medicine 65:1473−1486

doi: 10.1016/j.freeradbiomed.2013.07.020
[43]

Chen KL, Chang WS, Cheung CH, Lin CC, Huang CC, et al. 2012. Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Letters 317:89−98

doi: 10.1016/j.canlet.2011.11.015
[44]

Fei M, Zhang L, Wang H, Zhu Y, Niu W, et al. 2020. Inhibition of cathepsin S induces mitochondrial apoptosis in glioblastoma cell lines through mitochondrial stress and autophagosome accumulation. Frontiers in Oncology 10:516746

doi: 10.3389/fonc.2020.516746
[45]

Yang G, Driver JP, Van Kaer L. 2018. The role of autophagy in iNKT cell development. Frontiers in Immunology 9:2653

doi: 10.3389/fimmu.2018.02653
[46]

Pei B, Zhao M, Miller BC, Véla JL, Bruinsma MW, et al. 2015. Invariant NKT cells require autophagy to coordinate proliferation and survival signals during differentiation. Journal of Immunology 194:5872−5884

doi: 10.4049/jimmunol.1402154
[47]

Salio M, Puleston DJ, Mathan TSM, Shepherd D, Stranks AJ, et al. 2014. Essential role for autophagy during invariant NKT cell development. Proceedings of the National Academy of Sciences of the United States of America 111:E5678−E5687

doi: 10.1073/pnas.1413935112
[48]

Panzitt K, Jungwirth E, Krones E, Lee JM, Pollheimer M, et al. 2020. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. Journal of Hepatology 72:1122−1131

doi: 10.1016/j.jhep.2020.01.014
[49]

Qian H, Chao X, Williams J, Fulte S, Li T, et al. 2021. Autophagy in liver diseases: a review. Molecular Aspects of Medicine 82:100973

doi: 10.1016/j.mam.2021.100973